Zotarolimus| CAS 221877-54-9

Cas No.:	221877-54-9
Chemical Name:	Zotarolimus
Synonyms:	Rapamycin,42-deoxy-42-(1H-tetrazol-1-yl)-, (42S)-;Zotarolimus;zotarolimus(ABT-578);A179578;A-179578;ABT578;ABT-578;(42S)-42-Deoxy-42-(1H-tetrazol-1-yl)rapamycin;Resolute;42-(1-Tetrazolyl)rapamycin;ZOTAROLIMUS [USAN];ABT 578;ZOTAROLIMUS [INN];BDBM50174276;GTPL7974;Rapamycin, 42-deoxy-42-(1H-tetrazol-1-yl)-, (42S)-;Zotarolimus; ABT-578;SCHEMBL67389;UNII-H4GXR80IZE;EX-A2216;DTXSID50873387;ZOTAROLIMUS [WHO-DD];HY-12424;Zotarolimus, >90%;s7091;NCGC00386351-01;(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-12-[(2R)-1-[(1S,3R,4S)-3-methoxy-4-(1H-1,2,3,4-tetrazol-1-yl)cyclohexyl]propan-2-yl]-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0^{4,9}]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone;221877-54-9;AKOS037645037;ZOTAROLIMUS [MART.];Endeavor;CS-5715;H4GXR80IZE;CHEBI:135897;Zotarolimus (ABT-578);Mdt-4107;CHEMBL219410;A 179578;Q15410168;MFCD09752954;Zotarolimus [USAN:INN];CCG-270596;J-014574;zotarilumus;AS-56346;AC-31528;DTXCID40820906;(42S)-42-Deoxy-42-(1H-tetrazol-1-yl)rapamycin; 42-(1-Tetrazolyl)rapamycin; A 179578; ABT 578;;ZOTAROLIMUS (MART.);zotarolimusum;BRD-K46843573-001-01-9
SMILES:	CO[C@H]1[C@@H](N2C=NN=N2)CC[C@@H](C[C@H]([C@@](CC([C@@H](/C=C([C@H]([C@H](C([C@@H](C[C@@H]3C)C)=O)OC)O)\C)C)=O)([H])OC([C@@](CCCC4)([H])N4C(C([C@](O[C@]5([H])C[C@@H](/C(C)=C/C=C/C=C/3)OC)([C@@H](CC5)C)O)=O)=O)=O)C)C1
Formula:	C₅₂H₇₉N₅O₁₂
M.Wt:	966.21000
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

Zotarolimus (ABT-578, A 179578) is a semi-synthetic analogue of rapamycin, inhibits FKBP-12 binding with IC50 of 2.8 nM and shows less potent systemic immunosuppression than rapamycin; effectively inhibits both smooth muscle cell and endothelial cell proliferation, with IC50 values of 2.9 nM and 2.6 nM, respectively; exhibits high-affinity binding to the immunophilin FKBP12, inhibiting in vitro proliferation of both human and rat T cells; inhibits Con A-induced human T cells with IC50 of 7.0 nM; reduce early complications and improve late clinical outcomes in patients needing interventional cardiology.

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101

Cat. No.	Product name	Field of application
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75868	AZ14133346	AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865	TI17	TI17 represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
DC75816	Nisoxetine	Nisoxetine acts as a highly selective and potent noradrenaline transporter (NET) antagonist, exhibiting a binding affinity (Kd) of 0.76 nM. In addition to its antidepressant properties, nisoxetine functions as a local anesthetic by inhibiting voltage-gated sodium channels. This dual pharmacological activity makes it a compound of interest for both neurological and pain management research.
DC75641	GENZ-644282 TFA salt	Genz-644282, also known as SAR402674, is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.
DC75325	PSMA-617 TFA	PSMA-617, also know as vipivotide tetraxetan, is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC.
DC75202	Fosaprepitant free acid	Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74748	O4I4	O4I4 (compound 23) is a OCT4-inducing compound with metabolical stability.
DC74684	ZH8667	ZH8667 is a trace amine-associated receptor 1 (TAAR1)–Gs agonist.
DC74646	EB-PSMA-617	EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.